Dichotomous selection of high-level oxacillin resistance in Staphylococcus aureus by fluoroquinolones

International Journal of Antimicrobial Agents

Volumn 36, Issue 3, 2010, Pages 216-221

  Dalhoff, Axel ^a   Schubert, Sabine ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Dichotomous selection; Fluoroquinolones; High level oxacillin resistance; Staphylococcus aureus

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CIPROFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; OXACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COUNT; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EXPOSURE; GENE MUTATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STAPHYLOCOCCUS AUREUS; COMMUNITY ACQUIRED INFECTION; CROSS INFECTION; DRUG EFFECTS; GENETIC SELECTION; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; MICROBIOLOGY; PENICILLIN RESISTANCE; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; FLUOROQUINOLONES; HUMANS; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; OXACILLIN; SELECTION, GENETIC; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 77954951555     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.04.014     Document Type: Article

References (43)

1. Jevons M.P. Celbenin-resistant staphylococci. Br Med J 1961, 1:124-125.
2. Knox R. Celbenin-resistant staphylococci. Br Med J 1961, 1:126.
3. Lacey R.W. The mechanism of methicillin resistance. J Antimicrob Chemother 1986, 18:435-439.
4. Berger-Bächi B., Rohrer S. Factors influencing methicillin resistance in staphylococci. Arch Microbiol 2002, 178:165-171.
5. Tomasz A., Nachmann S., Leaf H. Stable classes of phenotypic expression in methicillin-resistant clinical isolates of staphylococci. Antimicrob Agents Chemother 1991, 35:124-129.
6. Utsui Y., Yokota T. Role of an altered penicillin-binding protein in methicillin- and cephem-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1985, 28:397-403.
7. Deresinski S. Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey. Clin Infect Dis 2005, 40:562-573.
8. Johnson A.P., Pearson A., Duckworth G. Surveillance and epidemiology of MRSA bacteraemia in the UK. J Antimicrob Chemother 2005, 56:455-462.
9. Marples R.R., Reith S. Methicillin-resistant Staphylococcus aureus in England and Wales. Commun Dis Rep CDR Rev 1992, 2:R25-R29.
10. Shanson D.C. Antibiotic-resistant Staphylococcus aureus. J Hosp Infect 1981, 2:11-36.
11. Hawkey P.M. The growing burden of antimicrobial resistance. J Antimicrob Chemother 2008, 62(Suppl. 1):i1-i9.
12. Superbugs and superdrugs: a history of MRSA 2008, vol. 32. Wellcome Trust Centre for the History of Medicine at UCL, London, UK.
13. Johnson A.P., Aucken H.M., Cavendish S., Ganner M., Wale M.C., Warner M., et al. Dominance of EMRSA-15 and -16 among MRSA causing nosocomial bacteraemia in the UK: analysis of isolates from the European Antimicrobial Resistance Surveillance System (EARSS). J Antimicrob Chemother 2001, 48:143-144.
14. Dziekan G., Hahn A., Thüne K., Schwarzer G., Schäfer K., Daschner F.D., et al. Methicillin-resistant Staphylococcus aureus in a teaching hospital: investigation of nosocomial transmission using a matched case-control study. J Hosp Infect 2000, 46:263-270.
15. Weber S.G., Gold H.S., Hooper D.C., Karchmer A.W., Carmeli Y. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalised patients. Emerg Infect Dis 2003, 9:1415-1422.
16. Graffunder E.M., Venezia R.A. Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J Antimicrob Chemother 2002, 49:999-1005.
17. Salgado C.D., Farr B.M., Calfee D.P. Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors. Clin Infect Dis 2003, 36:131-139.
18. Harbarth S., Frankhäuser C., Schrenzel J. Universal screening for methicillin-resistant Staphylococcus aureus at hospital admission and nosocomial infection in surgical patients. JAMA 2008, 299:1149-1157.
19. Tacconelli E., DeAngelis G., Cataldo M.A., Pozzi E., Cauda R. Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysis. J Antimicrob Chemother 2008, 61:26-38.
20. Dancer S.J. Importance of the environment in methicillin-resistant Staphylococcus aureus acquisition: the case for hospital cleaning. Lancet Infect Dis 2008, 8:101-113.
21. Dancer S.J. The role of environmental cleaning in the control of hospital-acquired infection. J Hosp Infect 2009, 73:378-385.
22. Crowcroft N.S. Methicillin-resistant Staphylococcus aureus and antimicrobial use in Belgian hospitals. Infect Control Hosp Epidemiol 1999, 20:31-36.
23. Niedersächsisches Landesamt, MRSA-Bedrohung durch Antibiotikatherapie? NLGA aktuell 2004;3:1-2.
24. Dalhoff A., Schubert S., Ullmann U. Effect of pH on the in vitro activity of and propensity for emergence of resistance to fluoroquinolones, macrolides, and a ketolide. Infection 2005, 33(Suppl. 2):36-43.
25. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 7th ed. Document M7-A7. Wayne, PA: CLSI; 2006.
26. Grasso S., Meinardi G., deCarneri I., Tamassia V. New in vitro model to study the effect of antibiotic concentration and rate of elimination on antibacterial activity. Antimicrob Agents Chemother 1978, 13:570-576.
27. Dalhoff A. Pharmacodynamics of fluoroquinolones. J Antimicrob Chemother 1999, 43(Suppl. B):51-59.
28. Schubert S., Dalhoff A., Stass H., Ullmann U. Pharmacodynamics of moxifloxacin and levofloxacin simulating human serum and lung concentrations. Infection 2005, 33(Suppl. 2):15-21.
29. Dalhoff A., Koeppe P., von Kobyletzki D. Studies on the pharmacokinetics of amoxicillin after intravenous, intramuscular and oral administration. Arzneimittelforschung 1981, 31:1148-1157. [in German].
30. Todd P.A., Benfield P. Amoxicillin/clavulanic acid. An update of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1990, 39:264-307.
31. Dudley M.N. Pharmacokinetics of fluoroquinolones. Quinolone antimicrobial agents 2003, 115-132. ASM Press, Washington, DC. 3rd ed. D.C. Hooper, E. Rubinstein (Eds.).
32. Stass H., Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother 1999, 43(Suppl. B):83-90.
33. Venezia R.A., Domaracki B.E., Evans A.M., Preston K.E., Graffunder E.M. Selection of high-level oxacillin resistance in heteroresistant Staphylococcus aureus by fluoroquinolones exposure. J Antimcrob Chemother 2001, 48:375-381.
34. Dalhoff A., Schmitz F.J. In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur J Clin Microbiol Infect Dis 2003, 22:203-221.
35. Thauvin-Eliopoulos C., Eliopoulos G.M. Activity in vitro of the quinolones. Quinolone antimicrobial agents 2003, 91-111. ASM Press, Washington, DC. 3rd ed. D.C. Hooper, E. Rubinstein (Eds.).
36. Schmitz F.J., Higgins P.G., Mayer S., Fluit A.C., Dalhoff A. Activity of quinolones against Gram-positive cocci: mechanisms of drug action and bacterial resistance. Eur J Clin Microbiol Infect Dis 2002, 21:647-659.
37. Goldstein E.J.C., Citron D.M., Warren Y.A., Tyrrell K.L., Rybak M.J. Virulence characteristics of community-associated Staphylococcus aureus and in vitro activities of moxifloxacin alone and in combination against community-associated and healthcare-associated meticillin-resistant and -susceptible S. aureus. J Med Microbiol 2008, 57:452-456.
38. Dalhoff A., Petersen U., Endermann R. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Chemotherapy 1996, 42:410-425.
39. Schaper K.J., Schubert S., Dalhoff A. Kinetics and quantification of antibacterial effects of β-lactams, macrolides and quinolones against Gram-positive and Gram-negative RTI pathogens. Infection 2005, 33(Suppl. 2):3-14.
40. Kayser F.H., Santanam P., Huf E. Comparative activity of moxifloxacin and other quinolones against staphylococci. Chemother J 2000, 9:114-119. [in German].
41. Graffunder E., Venezia R.A. Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J Antimicrob Chemother 2002, 49:999-1005.
42. Bisognano C., Vaudaux P.E., Lew D.P., Ng E.Y.W., Hooper D.C. Increased expression of fibronectin-binding proteins by fluoroquinolone-resistant Staphylococcus aureus exposed to subinhibitory levels of ciprofloxacin. Antimicrob Agents Chemother 1997, 41:906-913.
43. Bisognano C., Vaudaux P., Rohner P., Lew D.P., Hooper D.C. Inhibition of fibronectin-binding proteins and increased adhesion of quinolone-resistant Staphylococcus aureus by subinhibitory levels of ciprofloxacin. Antimicrob Agents Chemother 2000, 44:1428-1437.